Key result
Enalapril induced a greater reduction in minimal vascular resistance than simvastatin (-1.7 vs -0.6 AU) and a greater increase in forearm blood flow, with additive effects when combined.
Why the study?
Does enalapril, simvastatin, or their combination improve vascular reactivity and structural damage in hypercholesterolemic hypertensive subjects?
RCT (n=30)
Does enalapril, simvastatin, or their combination improve vascular reactivity and structural damage in hypercholesterolemic hypertensive subjects?
ACE inhibition with enalapril provides greater improvements in vascular reactivity and structural damage than simvastatin in hypercholesterolemic hypertensive patients, with additive benefits when combined.
Answers are grounded in this paper and cite their sources.
Enalapril may confer greater vascular benefits than simvastatin in hypercholesterolemic hypertension; leaves open additive effects on outcomes pending randomized trials.
Hypercholesterolemia and hypertension are frequently associated with elevated sympathetic activity. Both are independent cardiovascular risk factors and both affect endothelium-mediated vasodilation. To identify the effects of cholesterol-lowering and antihypertensive treatments on vascular reactivity and vasodilative capacity, we studied 30 hypercholesterolemic hypertensive subjects. They received placebo for 4 weeks, either enalapril or simvastatin for 14 weeks, and, finally, both medications for an additional 14 weeks. Postischemic forearm blood flow (MFBF) and minimal vascular resistance (mFVR) were used as indices of vasodilative capacity and structural vascular damage, respectively. Total (resting-stress-recovery phases) cardiovascular (blood pressure [BP] and heart rate [HR]) and regional hemodynamic (FBF and FVR) reactivity to stressful stimuli were calculated as area-under-the-curve (auc) (valuextime). Compared with baseline levels, simvastatin reduced total (TOT-C) and LDL cholesterol (LDL-C) (1.27 mmol/L, P<0.001 and 1.33 mmol/L, P<0.001, respectively). Enalapril also reduced TOT-C and LDL-C (0.6 mmol/L, P<0.001 and 0.58 mmol/L, P<0.05, respectively). MFBF was increased substantially by both treatments (P<0.001). Enalapril had a greater effect (-1.7 arbitrary units (AU), P<0.001) than simvastatin (-0.6 AU, P<0.05) on mFVR. During stress, FBF increased more with enalapril (4.4 FBFxminutes, P<0.001) than with simvastatin (1.8 FBFxminutes, P<0.01). Conversely, FVR stress response was reduced more with enalapril (9.1 FVRxminutes, P<0.001) than with simvastatin (2.9 FVRxminutes, P<0.01). During combination treatment, a significant (0.001>P<0.05) additive effect on hypercholesterolemia, structural vascular damage, BP, and FVR was shown. The findings suggest that angiotensin-converting enzyme (ACE) inhibition induces a larger reduction than HMG-CoA reductase blockade in vascular reactivity and structural damage in hypercholesterolemic hypertensive subjects.
No takes yet. Share an insight, caveat, or question.
Nazzaro et al. (1999) conducted an RCT in Hypercholesterolemia and hypertension (n=30). Enalapril and Simvastatin vs. Placebo was evaluated on Postischemic forearm blood flow (MFBF) and minimal vascular resistance (mFVR). Enalapril induced a greater reduction in minimal vascular resistance than simvastatin (-1.7 vs -0.6 AU) and a greater increase in forearm blood flow, with additive effects when combined.
Synapse has enriched 10 related papers. Consider them for comparative context: